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Purpose/Objective: During the course of their disease, 30-60% of lung 
cancer patients (pts) develop brain metastasis (BM). Despite local 
and/or systemic treatment survival is dismal. Depending on the 
Recursive Partitioning Analysis (RPA) class median survival is 7 months 
for class 1 and 3 months for class 3. In 2011 the Dutch national 
guideline on BM was revised, advising to actively treat pts with more 
than 3 BM both in RPA class 1 and the majority of pts in class 2 with 
Whole Brain Radiotherapy (WBRT). With lacking evidence of benefit, 
pts in RPA class 3 should be strictly treated palliatively. In this 
retrospective study in a large lung cancer patient cohort we evaluate 
the guideline’s use in daily practice. 
Materials and Methods: Data of all lung cancer pts who underwent 
WBRT for BM referred from one of three collaborating hospitals in the 
South of the Netherlands between March 2004 and July 2012 were 
retrospectively analyzed. Details on performance score (according to 
WHO/Karnofsky(KPS)), age, locally controlled disease, extracranial 
metastasis, time from diagnosis of lung cancer to development of BM, 
histology and survival after diagnosis of BM were collected. The RPA 
class was determined using the first four items. 
Results: 292 WBRT pts had NSCLC. Average age (range) was 62.6 years 
(40.5-83.5) , 59.2% was male, 252 (68.3%) had a KPS of ≥ 70. In 215 
(73.6%) pts the primary tumor was not controlled, 116 (39.7%) had 
extra-cranial metastasis, 93 (31.9%) had BM at primary diagnosis. 96 
WBRT pts had SCLC, average age was 62.1 years (44.7-83.5) , 64.0% 
was male, 86 (89.6%) had a KPS of ≥ 70. In 71 (74.0%) pts the primary 
tumor was not controlled, 37 (38.5%) had extracranial metastasis and 
24 (25.0%) had BM at primary diagnosis.  
For NSCLC, 45 (15.4%) of 292 pts were classified as RPA 1, 210 (71.9%) 
as RPA 2, and 37 (12.7%) as RPA 3. For SCLC this was 7 (7.3%), 75 
(78.1%), and 14 (14.6%), respectively. Before the revised guideline 
was implemented in 2011, on average 10.8% of WBRT pts were 
annually classified as RPA 3. In the year after implementing the 
guideline, this was 7.7 % (p=0,353). Median survival for NSCLC RPA 
class 1, 2, and 3 was 6.5 [95% CI = 3.8-9.2]; 3.0 [95% CI =2.3-3.7] and 
1.5 [95% CI = 0.7-2.2] months, respectively. For SCLC this was 9.0 [95% 
CI = 8.0-10.0]; 4.4 [95% CI = 2.9-6.0] and 2.0 [95% CI = 0.2-3.,8] 
months, respectively (see figure 1). 
 
 Figure1: Overall survival analysis. 
 
Conclusions: Although it is not advised that RPA class 3 pts should 
receive WBRT, approximately 13 % of the analyzed WBRT pts were 
classified as RPA 3. Despite the release/implementation of the new 
national guideline in 2011, we did not find a significant difference 
regarding the treatment of RPA class 3 pts thereafter. The survival of 
RPA class 3 pts is poor and in agreement with RTOG validation studies. 
In our view, guidelines should be implemented more precisely. Better 
awareness amongst physicians would prevent some patients from 
being treated unnecessarily. 
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Purpose/Objective: Standard treatment of locally advanced non-small 
cell lung cancer (NSCLC) corresponds to concomitant chemo-
radiotherapy (2 Gy per fraction until 60-66 Gy). A phase I trial was 
initiated in order to analyse toxicity of standard chemoradiotherapy 
(46 Gy, 2 Gy per fraction) with a stereotactic ablative radiotherapy 
(SABR) boost. The aim of the present study was to develop an 
algorithm able to determine biological equivalent dose received by 
every organ at risk and target volume during radiotherapy using two 
different fractionation schedules. 
Materials and Methods: A phase I trial began in our center in 2010 
and analyzes toxicity after chemoradiotherapy (46 Gy with docetaxel 
and cisplatinum, 2 Gy per fraction) and a boost delivered by SABR (3 X 
7 Gy for the first level, 3 X 12 Gy for the last level). Conventional 
treatment dose matrix and stereotactic dose matrix were fused on the 
same CT-scan (used for SABR treatment). Histogram dose volume was 
evaluated by summation of physical dose after biological conversion 
for each voxel by using the linear quadratic-linear model (LQ-L) and 
the α/β ratio of the delinated organ (ARTIVIEW, AQUILAB SAS, 
France). 
Results: With a median follow-up of 21 months (5-26), 14 patients 
(pts) were treated and 12 (85.7%) experienced grade 1-2 toxicities (no 
grade 3-4 toxicities). One patient died of massive hemoptysis 6 
months after treatment, but also after local and metastatic relapse, 
and bevacizumab treatment. The most frequent toxicity was G1-2 
pulmonary alveolitis (8 pts, 57.1%).When considering dose constraints 
used in conventional treatment, post-hoc analysis of matrix-dose 
revealed that bioequivalent cumulative dose were above the usual 
recommended dose in 3 pts for brachial plexus, 6 pts for pulmonary 
arteries, 4 for superior cave veinous, 2 for heart, 3 for bronchial tree, 
8 for bone, and 3 for lung. When comparing biological summation for 
both conventional and SABR treatment, with only conversion for the 
SABR part there was a median difference of -0.35 Gy (-5.1 ;+0.8). 
Patient with hemoptysis had the highest dose delivered to the big 
vessels (141.7 Gy). 
Conclusions: One toxic death was suspected in this trial and 
correlated with the highest dose received to the big vessels but other 
factors could also explain this event. Otherwise a lot of pts received a 
dose over the limit of dose constraint but with up to now, no grade 3-
5 toxicities suggesting that the LQ-L might not well predict toxicities 
when mixing conventional and SABR treatments, and might 
overestimate bioequivalent dose. This has to be confirmed with longer 
follow-up and a larger number of patients. 
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The last decade has shown a tremendous increase in technological 
developments in radiotherapy in which many types of advanced 
technology emerged. These steps forward concerned: 1) Access of RT 
departments to new diagnostic imaging equipment; 2) Installation of 
new treatment modalities allowing dose delivery that are more 
precise, faster or with greater biological effectiveness; 3) Availability 
of numerous QA devices to verify the dose delivery and patient 
position before or during their treatment; 4) Electronic data transfer. 
Not all potential improvements have led to large scale clinical 
implementation. Cost and reimbursement are obvious reasons, but the 
implementation of new treatment modalities depends also on the 
availability of sufficient expertise and manpower in a department.  
 A large number of physical, technical and clinical problems have to 
be solved before advanced technology can be used in an optimal way. 
For instance, combination of diagnostic imaging information may yield 
improved knowledge of the position of target volume and organs at 
risk, while more advanced optimization and dose calculation 
algorithms may allow better target coverage and sparing of organs at 
risk. However, knowing the possibilities and limitations of these 
procedures is a prerequisite for their safe use by the treatment 
planning team; a process in which medical physicists play an essential 
role. Implementation of new treatment modalities such as proton and 
carbon-ion therapy is still far from routine practice and requires 
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enormous efforts from medical physicists to optimize planning, 
delivery and particularly in-room imaging to fully profit from the 
theoretical advantages of hadrontherapy. But also numerous, albeit 
less spectacular, problems have to be solved when implementing 
improved photon therapy options such as advanced IMRT, SRS, and 
VMAT techniques including the use of new in-room imaging and 
dosimetry procedures. Furthermore, integration of time in planning 
and delivery has resulted in a shift from viewing the patient as a static 
rigid body towards a dynamic non-rigid entity. However, the current 
tools for the plan-of-the-day approach are not ideal and new 
automated and fast procedures for 4D planning, dose verification and 
in-room imaging can therefore be expected the coming period.  
Implementing advanced technology in radiotherapy needs the 
expertise from radiation oncologists, physicists and RTTs. There is 
however a delay in implementing advanced technology tools due to 
the lack of time these staff members have to become familiar with 
these new devices and procedures.  Because many aspects of using 
new technology are at the interface between research and routine 
clinical work, there is a special role of medical physicists in 
introducing these tools. Investigating problems related to the use of 
new technology requires a research approach of a medical physicist. 
However, an academic attitude to find a perfect solution is often not 
possible in a busy clinic. Many issues fight for priority such as high 
quality versus simplicity, accuracy versus complexity and specificity 
versus an overall solution. On the other hand, a considerable part of 
the routine clinical work of medical physicists such as QA 
measurements can be performed by people not having a PhD.   
In order to implement new treatment approaches in radiotherapy it is 
necessary to design a working environment in which it is easy for staff 
to become familiar with advanced technology. Furthermore, it can be 
expected that only those advanced technology solutions that are 
robust and simple have a chance to be implemented at a large scale in 
the clinic. More attention should therefore be paid to “translating” 
new technological findings into practical approaches that can be 
implemented in centers having limited resources. To select patient 
groups for which these advanced technology tools are particularly 
beneficial is another challenge the coming era. In all these processes 
medical physicists can and should play a vital role. 
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Starting my training at the Barmherzige Schwestern Hospital in Linz, 
Austria, in 1973 all Radium-LDR applications were performed by the 
gynecologists. At the Department of Radiation Oncology no 
brachytherapy was used. My first contact with LDR wires was in 1978. 
This was at the Inselspital Bern, Switzerland, with Prof. Dr. Veraguth, 
precisely in June and July 1978. His specialty was the head & neck 
region. A year later I spent 3 months at the MD Anderson Cancer 
Center, primarily at the Section of Experimental Radiotherapy. But I 
had the opportunity to accompany Prof. Luis Delclos, the 
brachytherapist at this institution. Applications were limited to the 
uterus and the vagina using Radium insertions, and to prostate cancer 
using permanent Gold seed implants. Again a year later I spent 3 
months at the University Clinic in Freiburg/Breisgau, Germany, to 
learn about Iodine seed implantations. Only 2 months later I 
introduced this method at my hospital in Linz, Austria, in cooperation 
with our urologists. A year later, in 1982, I attended the 
brachytherapy course in Leeds, organized by Dan Ash. And in the same 
year I spent several weeks at Prof. Bernard Pierquin’s department in 
Creteil, France, to be introduced to the LDR wire implantations in 
breast cancer patients. Immediately we started with this method in 
Linz.  
In 1980 we changed to a HDR source, only suited for gynecological 
tumours and in 1984 to a tiny source suited for interstitial implants. 
From this time on we performed HDR breast boosts, in the same 
manner like Dr. Jacobs from Saarbrücken, Germany. The short 
radiation time of 45 to 60 minutes was a significant advantage 
compared to up to several days in LDR wire implants. The localization 
of the tumour bed in the breast was difficult at this time. We could 
orient ourselves only by means of mammography, surgery reports and 
the scar. In 1991 we acquired our first treatment planning CT so that 
we could define the tumour bed precisely and could verify the correct 
position of the needles, enabling us to correct these positions if 
necessary. In 1997 we added applications to bronchus, esophagus and 
anal canal to our routine portfolio, mostly as a boost to external beam 
treatments. Seldom cases were implants into the lip, cheek, vocal 
cord, vaginal, rectal and anal recurrences, etc., in part as a boost and 
in part as a primary treatment. 
At the beginning of the HDR era I was criticized by renowned 
radiotherapists and radiobiologists. They predicted severe side effects 
of the implanted tissues and surroundings, in particular the breast, 
going as far as necrosis of the entire organ. We therefore started to 
follow up the patients in relative short intervals, resulting in a data 
set of more than 1000 breast boost patients (1984 to 2008). We 
noticed no severe side effects. In the course of the years the local 
recurrence rate dropped, very slowly but steadily. In the first two 
years we observed some telangiectasia and skin fibroses after needle 
implants too close to the skin. As a consequence we applied Iridium-
HDR-implants only in patients with deep seated tumours. Experience 
showed that the 10 Gy isodose should have a distance of at least 
15mm from the skin to spare late side effects. The cosmetic results 
are excellent and depend on primary tumour size, size of the implant 
and tumor bed location. 
With increasing numbers of patients in our data set we performed 
several studies. The results showed a high relevance of the node ratio 
and the PR negative status. Also tumour location resulted in 
significant differences in terms of local control and survival. In many 
breast trials and studies these factors are not mentioned as negative 
prognostic factors. 
Brachytherapy provides a wide range of activities in many regions as a 
primary treatment or as a boost to EBRT in many entities. Together 
with modern imaging methods highly conformal applications by 
interventional radiotherapy became possible with the advantage of 
the application of high curative doses and a relevant reduction of side 
effects to the surrounding tissues (e.g. in APBI trials). 
 
 SYMPOSIUM: HN RT IN THE FUTURE: THE ULTIMATE 
INDIVIDUALISATION  
  
SP-0101   
Redefining the role of TNM in the era of HPV, hypoxia markers and 
other non-anatomic prognostic and predictive factors 
B. O'Sullivan1 
1Princess Margaret Hospital, Radiation Oncology, Toronto, Canada  
  
Since its inception in the 1950s, the TNM stage classification has 
provided a language to describe anatomic extent of disease in 
jurisdictions across the world. TNM serves several important purposes 
in cancer control and treatment: these include assisting in the 
planning of treatment, evaluation of prognosis, exchange of 
information about cancer, and contributing to research and cancer 
control throughout the world. For these reason it is essential to the 
activities of numerous domains involved in clinical trials, registry and 
surveillance, education, and guideline development for many 
cancers. Generally, and this includes for head and neck malignancies, 
it has also become synonymous with prognosis. However TNM also has 
significant limitations that include an inability to describe biology or 
to fully predict response to treatments, especially chemotherapy and 
targeted therapies. At the same time the success of TNM seems to 
have compelled the oncology community to try to embed other 
prognostic information within it as one of the few models to convey 
prognosis and prediction. Therefore a major challenge today is the 
integration of non-anatomic factors with anatomic in a way that is 
meaningful and robust so that accurate and effective tools become 
available to guide individualized care.  If a strategy is not developed 
the danger is that neither will be addressed properly and activities 
requiring one dimension of knowledge (e.g. extent of disease for 
cancer registry and essential tumor assessment in the clinic) will 
potentially be compromised or diverse patient groups previously 
considered as similar (e.g. patients with hypoxic tumors or those with 
an entirely different disease such as HPV-driven cancers) will not be 
effectively stratified to deliver tailored treatments where they may 
be beneficial. At present the UICC and the AJCC are developing a 
framework for clinical use that acknowledges the description of 
extent of disease but also biological and pathological characteristics 
of the tumor and the host to permit inclusion of validated non-
anatomic prognostic and predictive factors, especially biomarkers, 
that may guide treatment. This will involve agreement on a lexicon of 
terms and criteria for classification into appropriate risk groups in 
models that will include factors relevant to the disease setting. 
Important for the latter will be application of essential 
epidemiological principles that address the nature of the disease (e.g. 
primary vs recurrent disease, early vs advanced presentations, the 
type of treatment being considered, and in some cases the end-point 
being addressed within a given risk model). New terms are required to 
enhance this process, and existing definitions in data structures such 
